Delaware | 001-34637 | 20-1852016 | ||
(State or other jurisdiction of | (Commission File Number) | (I.R.S. Employer | ||
incorporation) | Identification No.) |
25801 Industrial Boulevard, Suite B, Hayward, California | 94545 | |
(Address of principal executive offices) | (Zip Code) |
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Exhibit No. | Description | |
99.1
|
Press Release, dated August 4, 2010 |
2
Date: August 4, 2010 | Anthera Pharmaceuticals, Inc. |
|||
By: | /s/ Christopher P. Lowe | |||
Christopher P. Lowe | ||||
Chief Financial Officer and
Vice President of Administration |
Exhibit No. | Description | |
99.1
|
Press Release, dated August 4, 2010 |